A Phase Ib Clinical Study of AC-003 Capsules in Subjects With aGVHD.

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 25, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

September 30, 2026

Conditions

Acute Graft-versus-Host Disease

Interventions

DRUG

AC-003

AC-003 capsules will be administered orally.

Trial Locations (1)

RECRUITING

Hematology Hospital of Chinese Academy of Medical Sciences (Institute of Hematology, Chinese Academy of Medical Sciences), Tianjin

All Listed Sponsors

lead

Accro Bioscience (Suzhou) Limited

INDUSTRY